Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: A retrospective analysis of the French compassionate use program in 28 patients

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2399-2404

  Ghesquières, Hervé ^a   Stamatoullas, Aspasia ^b   Casasnovas, Olivier ^c   Morschhauser, Franck ^d   Gyan, Emmanuel ^e   Gabarre, Jean ^f   Malphettes, Marion ^g   Clément, Laurence ^h   Ferlay, Céline ^a   Brice, Pauline ^g  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Bendamustine; Hodgkin lymphoma; Refractory; Relapse

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; LENALIDOMIDE; NAVELBINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BRONCHITIS; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; COMPASSIONATE USE TRIALS; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885364984     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.776165     Document Type: Article

References (26)

1. Bnrchmann P, Engert A. The past: What we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010;2010: 10 1-107.
2. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin?s disease:Results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
3. Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin?s disease in 187 patients. Cancer 1996;78:1293-1299.
4. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin?s lymphoma registered in the database of the German Hodgkin?s lymphoma study group. J Clin Oncol 2002;20:221-230.
5. Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin lymphoma responding to prior salvage therapy. Haematologica 2012;97:1073-1079.
6. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin?s lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26:5980-5987.
7. Castagna L, Bramanti 5, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDGPET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009; 145:369-372
8. Mocikova H, Pytlik R, Markova J, et al. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 2011;52:1668-1674.
9. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665-1670.
10. Horning S, Fanale M, DeVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics:An international effort. Ann Oncol 2008;19(Suppl. 4): Abstract 118.
11. Currin ES, Gopal AK. Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. Korean J Hematol 2012;47:8-16.
12. Fehniger TA, Larson 5, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-5125.
13. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase 11 study of brentuximab vedotin for patients with relapsed or refractory Hodgkin?s lymphoma. J Clin Oncol 2012;30:2183-2189.
14. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin?s lymphoma after autologous stem-cell transplantation: Results of a phase 11 study. J Clin Oncol 2012;30:2197-2203.
15. Rummel MJ, Gregory SA. Bendamustine?s emerging role in the management of lymphoid malignancies. Semin Hematol 2011; 48(Suppl. 1):S24-S36.
16. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase 11I study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2009; 1 14(Suppl. 1): Abstract 405.
17. Walter E, Schmitt T, Dietrich 5, et al. Rituximab and bendamustine in patients with CD2O + diffuse large B-Cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012;53:2290-2292.
18. Borchmann P, Schnell R, Diehl V, et al. New drugs in the treatment of Hodgkin?s disease. Ann Oncol 1998;9(Suppl. 5):5103-5108.
19. Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase 11 study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:468-480.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin?s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
21. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
22. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin?s lymphoma. Results of the HDR-ALLO study -A prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-3 17.
23. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin?s disease: Results of a multicenter phase 11 study. J Clin Oncol 2000;18:2615-2619.
24. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin?s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-1079.
25. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141:3-13.
26. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: Outcomes and prognostic factors in the modern era. Blood 2012;119:692-695.